24/7 Market News Snapshot 03 September, 2025 – SiNtx Technologies, Inc. Common Stock (NASDAQ:SINT)

September 3, 2025

DENVER, Colo., 03 September, 2025 (www.247marketnews.com) – (NASDAQ:SINT) are discussed in this article.
SiNtx Technologies, Inc. (SINT) is experiencing a remarkable surge in pre-market trading, currently valued at $6.524, marking a 42.76% increase from the previous close of $4.570. This surge is accompanied by a hefty trading volume of 2.51 million shares, highlighting heightened investor interest and confidence. The notable ascent in price can be attributed to an optimistic market sentiment, likely influenced by recent advancements in the company’s innovative technologies.

One major factor driving this enthusiasm is the release of a pioneering peer-reviewed study showcasing the potent antiviral properties of silicon nitride, a key focus of SINT’s biomedical advancements. Conducted in collaboration with Professor Kylene Kehn-Hall of Virginia Polytechnic Institute and State University, the research indicates that silicon nitride demonstrates significant efficacy against various infectious strains, including SARS-CoV-2 and MERS-CoV. Specifically, the study reveals that silicon nitride can achieve a remarkable 99.97% reduction in infectious SARS-CoV-2 within a mere 10 minutes of contact, with complete inactivation realized in 30 minutes. Furthermore, silicon nitride incorporated into textile fabric exhibited a 97% virucidal effect, affirming its compatibility with vital medical devices and personal protective equipment (PPE).

Dr. Ryan Bock, Chief Technology Officer at SINTX Technologies, remarked on the study’s implications, expressing that silicon nitride is evolving beyond its role as a premier implant material to become a versatile antiviral platform. As the global infection prevention and control market is expected to surpass $230 billion by 2032, SINTX is strategically positioned to leverage its FDA-cleared, ISO-certified silicon nitride technology, fulfilling the demand for sustainable and effective solutions. With ambitions to broaden its scope beyond orthopedic implants, SINTX is actively seeking partnerships and licensing opportunities, paving the way for significant advancements and market presence in the near future.

Related news for (SINT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.